Multimorbidity in #RA - VARA registry data- looking at 61 different biomarkers and 44 comorbidities Chronic pain in 44% Specific biomarkers seen in different morbidities @rheumnow #ACR23 session#13M148 https://t.co/l6FU1ELKD3

Peyton et al.: 4 multimorbidity patterns in RA -Mental health and subst abuse -Metabolic -CV -Chronic pain All associated with different sets of biomarkers. Some are very specific of one profile while others are widespread across profiles. @RheumNow #ACR23 ABST1631 https://t.co/VqCrLI3oyy

Ultrasound (and specifically intima-media thickness) might not just be for diagnosis in GCA - it might be a GCA disease activity measure for monitoring: - improves over time - increases with flares Valentin Schaefer #ACR23 ABST1649 @RheumNow https://t.co/QWdIVGrHbn

Ross et al. Ultrasound assessed Optic nerve sheath measurement in GCA. Previously shown increased in GCA. Here decreases with treatment shown in 9 patients Abstr#1650 #ACR23 @RheumNow https://t.co/fcrS4tT6U0 https://t.co/ylnPKzdUe0

In PS-matched study, no significant difference in respiratory hospitalisation or death between RA-ILD patients on non-TNFi/JAKi vs. TNFi. This finding does not support systematic avoidance of TNFi in RA-ILD, England B Abst#1582 #ACR23 #ACRBest @RheumNow https://t.co/1zVjMWNZZS https://t.co/d8TRIvGaIe

Fate of ANA+/UCTD A#1449 #ACR23 @RheumNow 207 asymptomatic ANA+ or UCTD followed - <10% progress to SARD, 90% did not Progression to SLE (11 pt), Sjo (5), SSc (3), RA (1) Progressors to SLE: arthritis (91%), low compl (45%), alopecia (36%), ulcers (27%) - milder manifestations

Abst#1583 SMART study: Split dose qwk MTX (10 mg QAM, 15 mg QPM) may have better efficacy compared to 25 mg single dose qwk MTX. RCT 253 RA patients: split dose had better DAS score, less likely to add other DMARDS, but slight⬆️in LFTs. #Plenary #ACR23 @rheumnow #ACRbest

Visit RheumNow's Booth at #ACR23 https://t.co/7HuNpWtf0M https://t.co/INtMGvEkA3

• Visit RheumNow's Booth at ACR Convergence 2023 | RheumNow

Evidence of window of opportunity concept in PsA. Certainly >52 weeks delay associates with worse outcomes. <12 weeks and 12-52 weeks similar. Abstr#1641 #ACR23 @RheumNow https://t.co/fMb3D9zl8B https://t.co/rHu29Eflo0

FDG-PET uptake at baseline in GCA predicts future risk of future thoracic aneurysm In print here: https://t.co/2SQm18y6zP Could this help stratify aneurysmal screening? #ACR23 ABST1647 @RheumNow https://t.co/p1Dhkm2WTX

• Association Between Vascular 18F-Fluorodeoxyglucose Uptake at Diagnosis and Cha…

It's OK to use TNFi in RA-ILD! VA study 1000+ pts using Target Trial Emulation framework: TNFi vs nonTNFi biologics/JAKi followed for 3 years. NO differences in respiratory hospitalizations or deaths or all cause mortality. abst#1582 #ACR23 #ACRbest @rheumnow https://t.co/aI2SmMrLPE

Wolfgang Schmidt presenting @eular_org large vessel vasculitis imaging recommendations at #ACR23, acknowledging @ACRheum on the way. Great to see a master (& a new ACR Master) navigate with clarity, uniting different sides of the Atlantic. @RheumNow https://t.co/hyAcX8GSWf